Skip to Content


Prospective Grant of Exclusive License: Use of Thymosin β4 for Wound Healing Applications; Correction

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

The notice published in the February 28, 2000 Federal Register—announcing the prospective grant of an exclusive license for use of thymosin β4 for wound healing applications (65 FR 10505)—incorrectly listed one of the serial numbers for the subject invention as “60/094,960” under the SUMMARY section. NIH is publishing this notice to correct this serial number to read “60/094,690.” In view of this correction, to allow interested parties adequate time to respond, the DATES section is also amended to read “Only written comments and/or license applications Start Printed Page 13014which are received by the National Institutes of Health on or before June 8, 2000 will be considered.”

Start Signature

Dated: March 6, 2000.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

End Signature End Preamble

[FR Doc. 00-5785 Filed 3-9-00; 8:45 am]